Codon Optimized Factor VIII Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hemophilia A treatment is hindered by the high cost and inefficiency of commercial production of recombinant Factor VIII protein due to poor expression in heterologous systems, leading to frequent and inconvenient administration for patients.
Innovation Solution
Development of nucleic acid molecules with optimized sequences for Factor VIII activity, including increased codon adaptation index, reduced MAR/ARS sequences, and absence of destabilizing elements, to enhance expression and yield in host cells such as CHO and HEK293 cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If recombinant FVIII protein is produced in heterologous expression systems, then treatment cost can be reduced, but expression level is two to three orders of magnitude lower than similarly sized proteins
Solution Approach 1:
The patent applies codon optimization to change the nucleotide sequence parameters of the FVIII gene, replacing rare codons with more frequently used codons in mammalian cells. This parameter change in the genetic code increases translation efficiency and expression levels while maintaining the same amino acid sequence, thereby resolving the contradiction between reduced production cost and low expression level in heterologous systems.
Solution Approach 2:
The patent removes cis-acting elements from the FVIII coding sequence that inhibit expression, including transcriptional silencer elements, matrix attachment-like sequences (MARs), and transcriptional elongation inhibitory elements. By extracting these harmful regulatory elements, the patent enables significantly higher expression levels in heterologous mammalian cell systems, making recombinant production economically viable.
2Reliability
If FVIII is administered frequently (two to three times weekly for prophylaxis, one to three times daily for on-demand treatment), then bleeding episodes can be controlled, but treatment convenience deteriorates
Solution Approach 1:
The patent extends the plasma half-life of FVIII by modifying its molecular parameters through fusion with long-half-life proteins (albumin, IgG Fc region, transferrin) or PEGylation. These parameter changes in the protein structure enable less frequent administration (every 1-2 weeks instead of daily or weekly), maintaining reliable bleeding control while dramatically improving treatment convenience and patient quality of life.
Data Source
AI summary
The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.